Syntegra Private Wealth Group LLC Buys 61 Shares of Amgen Inc. $AMGN

Syntegra Private Wealth Group LLC increased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 5.0% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,284 shares of the medical research company’s stock after buying an additional 61 shares during the quarter. Syntegra Private Wealth Group LLC’s holdings in Amgen were worth $359,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Liberty One Investment Management LLC raised its stake in shares of Amgen by 3.5% in the second quarter. Liberty One Investment Management LLC now owns 16,724 shares of the medical research company’s stock valued at $4,669,000 after purchasing an additional 563 shares in the last quarter. apricus wealth LLC raised its stake in shares of Amgen by 2.8% in the 2nd quarter. apricus wealth LLC now owns 13,628 shares of the medical research company’s stock valued at $3,805,000 after buying an additional 367 shares in the last quarter. Klingman & Associates LLC lifted its holdings in shares of Amgen by 37.4% during the 2nd quarter. Klingman & Associates LLC now owns 1,855 shares of the medical research company’s stock worth $518,000 after acquiring an additional 505 shares during the period. Pittenger & Anderson Inc. boosted its position in shares of Amgen by 16.3% during the 2nd quarter. Pittenger & Anderson Inc. now owns 2,860 shares of the medical research company’s stock valued at $799,000 after acquiring an additional 400 shares in the last quarter. Finally, Avidian Wealth Enterprises LLC raised its position in Amgen by 18.0% in the second quarter. Avidian Wealth Enterprises LLC now owns 5,820 shares of the medical research company’s stock worth $1,625,000 after purchasing an additional 887 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on AMGN. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $305.00 price objective on shares of Amgen in a report on Tuesday, June 24th. Piper Sandler upped their price target on Amgen from $328.00 to $342.00 and gave the company an “overweight” rating in a research report on Monday, August 25th. Citigroup lifted their price objective on Amgen from $310.00 to $315.00 and gave the company a “neutral” rating in a report on Wednesday, September 24th. UBS Group lowered their target price on shares of Amgen from $326.00 to $317.00 and set a “neutral” rating on the stock in a report on Wednesday, August 6th. Finally, Bank of America lifted their price target on shares of Amgen from $261.00 to $272.00 and gave the company an “underperform” rating in a report on Friday, September 26th. Six equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Amgen currently has an average rating of “Hold” and a consensus target price of $300.94.

Amgen Trading Up 1.5%

Shares of AMGN opened at $303.33 on Tuesday. The stock’s fifty day simple moving average is $287.51 and its 200-day simple moving average is $287.05. The firm has a market capitalization of $163.30 billion, a PE ratio of 24.80, a price-to-earnings-growth ratio of 2.64 and a beta of 0.49. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $335.88. The company has a quick ratio of 0.98, a current ratio of 1.31 and a debt-to-equity ratio of 7.24.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, August 5th. The medical research company reported $6.02 earnings per share for the quarter, topping the consensus estimate of $5.28 by $0.74. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The firm had revenue of $9.18 billion during the quarter, compared to analysts’ expectations of $8.86 billion. During the same period in the previous year, the business posted $4.97 EPS. The company’s quarterly revenue was up 9.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. As a group, research analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, September 12th. Shareholders of record on Friday, August 22nd were issued a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a yield of 3.1%. The ex-dividend date of this dividend was Friday, August 22nd. Amgen’s payout ratio is currently 77.84%.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,267 shares of the company’s stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $296.99, for a total transaction of $376,286.33. Following the completion of the sale, the senior vice president owned 7,209 shares in the company, valued at approximately $2,141,000.91. The trade was a 14.95% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.69% of the company’s stock.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.